6CM
TCRT icon

683 Capital Management’s Alaunos Therapeutics TCRT Stock Holding History

683 Capital Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-667
Closed -$428K – 180
2019
Q3 		$428K Sell
667
-333
-33% -$264K 0.05% 100
2019
Q2 		$875K Sell
1,000
-333
-25% -$229K 0.08% 105
2019
Q1 		$770K Buy
+1,333
New +$557K 0.07% 100

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

683 Capital Management's TCRT Position: Q4 2019 in Review

683 Capital Management sold out of Alaunos Therapeutics (TCRT) in Q4 2019, closing a stake of 667 shares — an estimated $428K sold.

683 Capital Management first reported a position in TCRT in Q1 2019 and held it in 3 quarters. The position peaked at $875K in Q2 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q4 2019.

  • 683 Capital Management reported no remaining Alaunos Therapeutics position as of Q4 2019 after selling out during the quarter.
  • 683 Capital Management sold 667 Alaunos Therapeutics shares in Q4 2019, an estimated $428K.
  • 683 Capital Management first reported a position in Alaunos Therapeutics in Q1 2019 and held it in 3 quarters.
  • 683 Capital Management's Alaunos Therapeutics position peaked at $875K in Q2 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2019.

Based on 683 Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.